Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 13, 2026
DataAggregated Company Financials
Companies21
  • 7D8.0%
  • 3M4.0%
  • 1Y-33.0%
  • YTD12.1%

Over the last 7 days, the Healthcare industry has risen 8.5%, driven by gains from Novo Nordisk of 9.3%. During this same period, the Zealand Pharma underperformed, falling 8.2%. However, the industry is down 33% over the past year. Earnings are forecast to grow by 5.3% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 13 Jan 2026DKK 2.2tDKK 453.9bDKK 136.9b18x16x4.8x
Thu, 11 Dec 2025DKK 1.9tDKK 454.0bDKK 137.0b17.1x13.7x4.1x
Sat, 08 Nov 2025DKK 1.8tDKK 451.6bDKK 134.3b17.6x13.2x3.9x
Mon, 06 Oct 2025DKK 2.2tDKK 447.3bDKK 141.7b18.3x15.5x4.9x
Wed, 03 Sep 2025DKK 2.1tDKK 447.5bDKK 141.8b23.9x14.6x4.6x
Fri, 01 Aug 2025DKK 1.8tDKK 423.9bDKK 124.7b29.2x14.8x4.4x
Sun, 29 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Tue, 27 May 2025DKK 2.5tDKK 424.3bDKK 125.1b25.1x20x5.9x
Thu, 24 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.6x18.7x5.5x
Sat, 22 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.4x6.9x
Mon, 17 Feb 2025DKK 3.0tDKK 409.9bDKK 121.5b26.3x24.9x7.4x
Wed, 15 Jan 2025DKK 3.2tDKK 387.5bDKK 111.3b28.9x28.6x8.2x
Fri, 13 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.8x36.1x10.4x
Sun, 10 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Tue, 08 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.6x11.1x
Thu, 05 Sep 2024DKK 4.6tDKK 371.9bDKK 107.2b35.3x43.2x12.4x
Sat, 03 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b36.6x42x12.6x
Mon, 01 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b35.1x47.4x14.2x
Wed, 29 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.2x43.6x13x
Fri, 26 Apr 2024DKK 4.4tDKK 341.4bDKK 99.6b32.8x44.3x12.9x
Sun, 24 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Tue, 20 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.9x44.7x13x
Thu, 18 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42.1x11.8x
Sat, 16 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b32.9x38.7x10.9x
Mon, 13 Nov 2023DKK 3.6tDKK 319.8bDKK 89.9b31.7x39.6x11.1x
Wed, 11 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b34.2x41.7x11.2x
Fri, 08 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b36.3x43.3x11.6x
Sun, 06 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Tue, 04 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b39.7x39.3x10.3x
Thu, 01 Jun 2023DKK 3.1tDKK 287.2bDKK 75.5b41x40.6x10.7x
Sat, 29 Apr 2023DKK 3.1tDKK 272.6bDKK 69.0b44.7x45.1x11.4x
Mon, 27 Mar 2023DKK 2.9tDKK 291.2bDKK 69.0b36.7x42.1x10x
Wed, 22 Feb 2023DKK 2.8tDKK 289.4bDKK 68.9b40.5x40.8x9.7x
Fri, 20 Jan 2023DKK 2.7tDKK 276.0bDKK 66.3b38.4x41x9.8x
Price to Earnings Ratio

41x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 276.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.1x which is lower than its 3-year average PE of 33.8x.
  • The 3-year average PS ratio of 9.5x is higher than the industry's current PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market4.48%
Healthcare7.98%
Pharma8.89%
Medical Equipment4.73%
Biotech4.22%
Healthtech1.23%
Life Sciences-0.25%
Healthcare Services-14.69%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 234x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 94% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 379.109.3%
+DKK 143.7b		-38.2%PE16.2x
GMAB GenmabDKK 2.16k7.6%
+DKK 9.4b		38.3%PE13.1x
COLO B ColoplastDKK 573.805.8%
+DKK 7.1b		-28.0%PE35.6x
DEMANT DemantDKK 225.604.4%
+DKK 2.0b		-20.3%PE18x
HLUN B H. LundbeckDKK 44.023.3%
+DKK 1.4b		11.2%PE11.5x

Latest News

AMBU B
DKK 89.40
Ambu
7D
2.2%
1Y
-33.8%

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).
HLUN B
DKK 44.02
H. Lundbeck
7D
3.3%
1Y
11.2%

HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook

Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.
ZEAL
DKK 410.50
Zealand Pharma
7D
-8.2%
1Y
-41.3%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
COLO B
DKK 573.80
Coloplast
7D
5.8%
1Y
-28.0%

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
NOVO B
DKK 379.10
Novo Nordisk
7D
9.3%
1Y
-38.2%

NOVO B: Future Returns Will Rely On Oral Obesity Treatment And Legal Risks

Narrative Update Analysts have nudged their fair value estimate for Novo Nordisk slightly lower, from $393.04 to $392.29, as small adjustments to revenue growth, profit margin, and future P/E assumptions result in a marginally reduced price target. Analyst Commentary Recent tweaks to fair value for Novo Nordisk reflect relatively modest shifts in assumptions rather than a major change in the overall thesis.
GUBRA
DKK 491.00
Gubra
7D
-7.9%
1Y
-27.8%
DEMANT
DKK 225.60
Demant
7D
4.4%
1Y
-20.3%

DEMANT: Future Earnings Resilience Will Rely On Stable Market Position

Analysts have trimmed their price target on Demant slightly from DKK 271.65 to DKK 268. This reflects modestly softer assumptions for revenue growth and future P/E, partly offset by a marginally higher expected profit margin and recent views that organic revenue share gains may be limited for now.
BAVA
DKK 198.55
Bavarian Nordic
7D
2.9%
1Y
1.8%

BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside

Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.
GMAB
DKK 2,162.00
Genmab
7D
7.6%
1Y
38.3%

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
SMSMED
DKK 3.60
Scandinavian Medical Solutions
7D
-14.7%
1Y
-35.0%
VIRO
DKK 12.60
ViroGates
7D
-5.3%
1Y
-16.0%
CHEMM
DKK 719.50
ChemoMetec
7D
5.3%
1Y
40.7%